Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Decision making with regard to thromboprophylaxis should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient. As a consequence, a crucial part of atrial fibrillation (AF) management requires the appropriate use of thromboprophylaxis, and the assessment of stroke as well as bleeding risk can help inform management decisions by clinicians. The objective of this review article is to provide an overview of stroke and bleeding risk assessment in AF. There would be particular emphasis on when, how, and why to use these risk stratification schemes, with a specific focus on the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)], CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 and sex category (female)], and HAS-BLED [hypertension (i.e. uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR (if on warfarin), elderly (e.g. age >65, frail condition), drugs (e.g. aspirin, NSAIDs)/alcohol concomitantly] risk scores.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Self-citationLip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citationKearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“one trial with an NOAC, apixaban, among AF patients who had refused, failed, or deemed ineligible for warfarin, was superior to aspirin 81–324 mg daily, with similar rates of major bleeding and intracranial haemorrhage.(26) Nonetheless, an appreciation of”
BackgroundMant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Self-citation
Cited by
Goette, A., Kalman, J. M., Aguinaga, L., Akar, J., Cabrera, J. A., Chen, S. A., Chugh, S. S., Corradi, D., D’Avila, A., Dobrev, D., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2016.05.028 · Cited by 771
Self-citationGoette, A., Kalman, J. M., Aguinaga, L., Akar, J., Cabrera, J. A., Chen, S. A., Chugh, S. S., Corradi, D., D'Avila, A., Dobrev, D., et al. (2016) · Europace · doi:10.1093/europace/euw161 · Cited by 762
Self-citationStroke prevention in atrial fibrillation
Freedman, B., Potpara, T. S., & Lip, G. Y. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31257-0 · Cited by 463
Self-citationBoriani, G., Glotzer, T. V., Santini, M., West, T. M., De Melis, M., Sepsi, M., Gasparini, M., Lewalter, T., Camm, J. A., & Singer, D. E. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht491 · Cited by 427
Boriani, G., Laroche, C., Diemberger, I., Fantecchi, E., Popescu, M. I., Rasmussen, L. H., Sinagra, G., Petrescu, L., Tavazzi, L., Maggioni, A. P., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.11.026 · Cited by 338
Self-citationStroke Prevention in Atrial Fibrillation: A Systematic Review
Lip, G. Y. H., & Lane, D. A. (2015) · JAMA · doi:10.1001/jama.2015.4369 · Cited by 322
Self-citationLip, G. Y. H., Laroche, C., Ioachim, P. M., Rasmussen, L. H., Vitali-Serdoz, L., Petrescu, L., Darabantiu, D., Crijns, H. J. G. M., Kirchhof, P., Vardas, P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu374 · Cited by 237
“For example, the original historical trials of stroke prevention in AF conducted 20 years ago only randomized ,10% of patients screened, and many stroke risk factors were neither recorded nor consistently defined.(3) Even contemporary stroke prevention trials with non-valvular AF have excluded patients with severe ren…”
MethodSelf-citationLip, G. Y. H., Skjøth, F., Rasmussen, L. H., & Larsen, T. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.044 · Cited by 171
Lip, G. Y. H., Haguenoer, K., Saint-Etienne, C., & Fauchier, L. (2014) · Chest · doi:10.1378/chest.13-2976 · Cited by 120
Self-citationAtrial flutter and thromboembolic risk: a systematic review
Vadmann, H., Nielsen, P. B., Hjortshøj, S. P., Riahi, S., Rasmussen, L. H., Lip, G. Y. H., & Larsen, T. B. (2015) · Heart · doi:10.1136/heartjnl-2015-307550 · Cited by 72
Self-citationPhilippart, R., Brunet-Bernard, A., Clementy, N., Bourguignon, T., Mirza, A., Babuty, D., Angoulvant, D., Lip, G. Y. H., & Fauchier, L. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv163 · Cited by 68
Self-citationLip, G. Y. H., Clementy, N., Pierre, B., Boyer, M., & Fauchier, L. (2015) · Chest · doi:10.1378/chest.14-2096 · Cited by 26
Self-citation
Metadata
- Authors
- Lip, G. Y. H.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-20
- Volume
- 34
- Issue
- 14
- Pages
- 1041-1049
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2126573468
- Cited by
- 157
- References
- 23
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.